Nielsen Kirk G. 4/A
4/A · SpyGlass Pharma, Inc. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
SpyGlass (SGP) Director Kirk G. Nielsen Converts 3.15M Preferred Shares
What Happened
Kirk G. Nielsen, a director of SpyGlass Pharma, reported the conversion (transaction code C) of a total of 3,145,619 derivative/preferred shares into common stock on February 9, 2026. The filing shows four conversion entries (1,690,230; 548,067; 548,067; 359,255). No cash price or sale proceeds are reported because these were automatic conversions of preferred into common prior to the company's IPO.
Key Details
- Transaction date: February 9, 2026 (conversion entries)
- Transaction type: Conversion of derivative securities (code C) — no price per share reported (automatic one-for-one conversion).
- Total shares converted: 3,145,619 common shares.
- Shares owned after transaction: Not specified in this amended filing.
- Footnote F1: The preferred shares automatically converted one-for-one into common stock before the IPO without additional consideration.
- Footnote F2: Some or all of these shares are held directly by Vensana Capital I, L.P.; Nielsen is identified as a managing director of the general partner and may be deemed to share voting/investment power but disclaims beneficial ownership.
- Amendment: This Form 4 amends a prior Form 4 (filed Feb 10, 2026) to correct the number of shares reported in Table II.
Context
- Conversion (code C) here means preferred stock was turned into common stock as part of the IPO mechanics — not a purchase or a sale. No immediate market-direction signal should be inferred from a mandatory conversion.
- The amendment corrects reported counts; the filing does not show an open-market trade, exercise for cash, or any gift/withholding event.
Insider Transaction Report
Form 4/AAmended
Nielsen Kirk G.
Director
Transactions
- Conversion
Series B Preferred Stock
[F1][F2]2026-02-09−1,690,230→ 0 total(indirect: See footnote)→ Common Stock (1,690,230 underlying) - Conversion
Series C-1 Preferred Stock
[F1][F2]2026-02-09−548,067→ 0 total(indirect: See footnote)→ Common Stock (548,067 underlying) - Conversion
Series C-2 Preferred Stock
[F1][F2]2026-02-09−548,067→ 0 total(indirect: See Footnote)→ Common Stock (548,067 underlying) - Conversion
Series D Preferred Stock
[F1][F2]2026-02-09−359,255→ 0 total(indirect: See Footnote)→ Common Stock (359,255 underlying)
Holdings
- 3,310,619(indirect: See footnote)
Common Stock
[F2]
Footnotes (2)
- [F1]All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date.
- [F2]These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Signature
/s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen|2026-02-11